Interestingly, a well-established histone deacetylase inhibitor, suberoylanilide hydroxamic acid, can activate lysosomal function in human cancer cells by enhancing TFEB acetylation at K91, K103, K116, and K430 [45]. This evidence concerns the gene TFEB and cancer.